Future Medicine  Co., Ltd. Logo

Future Medicine Co., Ltd.

Clinical-stage biopharma developing novel synthetic drugs for inflammation, fibrosis, and oncology.

341170 | KO

Overview

Corporate Details

ISIN(s):
KR7341170009
LEI:
Country:
South Korea
Address:
경기도 성남시 수정구 창업로 54 619호, 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Future Medicine Co., Ltd. is a clinical-stage biopharmaceutical company focused on the development of novel synthetic drugs. The company utilizes its proprietary FOCUSTM (Futuremedicine Origin Compound Universal System) platform, a technology based on nucleoside chemistry, to discover and regulate various in vivo targets. Its therapeutic pipeline addresses unmet medical needs in areas such as inflammation and fibrosis, including treatments for diabetic nephropathy and primary biliary cholangitis (PBC), as well as oncology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-06-23 00:00
Regulatory News Service
기업설명회(IR)개최결과
Korean 6.6 KB
2025-06-17 00:00
Regulatory News Service
본점소재지변경
Korean 5.1 KB
2025-06-09 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 7.0 KB
2025-03-28 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 20.7 KB
2025-03-28 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 9.9 KB
2025-03-20 00:00
Audit Report / Information
감사보고서제출
Korean 16.0 KB
2025-03-20 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 333.9 KB
2025-03-13 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 164.6 KB
2025-03-13 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 10.8 KB
2025-03-13 00:00
Pre-Annual General Meeting Information
주주총회집중일개최사유신고
Korean 5.1 KB
2024-12-16 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.1 KB
2024-12-06 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 22.8 KB
2024-11-29 00:00
Regulatory News Service
기업설명회(IR)개최결과
Korean 6.6 KB
2024-11-21 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 7.0 KB
2024-07-19 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 23.0 KB

Automate Your Workflow. Get a real-time feed of all Future Medicine Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Future Medicine Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Future Medicine Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Elicera Therapeutics AB Logo
Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.
Sweden
ELIC
ELI LILLY & Co Logo
Pharma leader developing medicines for diabetes, obesity, oncology, and neuroscience.
United States of America
LLY
Ellen AB Logo
Develops research-based probiotic and prebiotic products for women's intimate health and pH balance.
Sweden
ELN
ELUTIA INC. Logo
Develops drug-eluting biologics to reduce complications from medical implants.
United States of America
ELUT
Emergent BioSolutions Inc. Logo
Develops and manufactures medical countermeasures for public health and national security threats.
United States of America
EBS
ENANTA PHARMACEUTICALS INC Logo
Developing novel small molecule drugs for virology (HCV, RSV) and immunological diseases.
United States of America
ENTA
enGene Holdings Inc. Logo
Developing non-viral, locally administered gene therapies for rare genetic conditions.
United States of America
ENGN
Enliven Therapeutics, Inc. Logo
A clinical-stage biopharma developing kinase inhibitors for precision oncology cancer treatment.
United States of America
ELVN
Enlivex Therapeutics Ltd. Logo
Developing cell therapy that reprograms macrophages to treat immune hyper-responses like sepsis.
United States of America
ENLV
Enlivex Therapeutics Ltd. Logo
Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.
Israel
ENLV

Talk to a Data Expert

Have a question? We'll get back to you promptly.